Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 185

Similar articles for PubMed (Select 23409128)

1.

Angiogenin in Parkinson disease models: role of Akt phosphorylation and evaluation of AAV-mediated angiogenin expression in MPTP treated mice.

Steidinger TU, Slone SR, Ding H, Standaert DG, Yacoubian TA.

PLoS One. 2013;8(2):e56092. doi: 10.1371/journal.pone.0056092. Epub 2013 Feb 7.

2.

Neuroprotection by tetrahydroxystilbene glucoside in the MPTP mouse model of Parkinson's disease.

Zhang L, Huang L, Chen L, Hao D, Chen J.

Toxicol Lett. 2013 Oct 24;222(2):155-63. doi: 10.1016/j.toxlet.2013.07.020. Epub 2013 Aug 1.

PMID:
23911879
3.
4.

A neuroprotective role for angiogenin in models of Parkinson's disease.

Steidinger TU, Standaert DG, Yacoubian TA.

J Neurochem. 2011 Feb;116(3):334-41. doi: 10.1111/j.1471-4159.2010.07112.x. Epub 2010 Dec 22.

5.

The peptidyl-prolyl isomerase Pin1 up-regulation and proapoptotic function in dopaminergic neurons: relevance to the pathogenesis of Parkinson disease.

Ghosh A, Saminathan H, Kanthasamy A, Anantharam V, Jin H, Sondarva G, Harischandra DS, Qian Z, Rana A, Kanthasamy AG.

J Biol Chem. 2013 Jul 26;288(30):21955-71. doi: 10.1074/jbc.M112.444224. Epub 2013 Jun 10.

6.

Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model.

Tasaki Y, Yamamoto J, Omura T, Sakaguchi T, Kimura N, Ohtaki K, Ono T, Suno M, Asari M, Ohkubo T, Noda T, Awaya T, Shimizu K, Matsubara K.

Neurosci Lett. 2012 Jul 11;521(1):15-9. doi: 10.1016/j.neulet.2012.05.045. Epub 2012 May 19.

PMID:
22617635
7.

[Effect of phosphorylated c-Jun expression on COX-2 expression in the substantia nigra of MPTP mouse model of subacute Parkinson disease].

Wang YS, Zhou JP, Wei ZF, Tian QY, Zhou HX, Zhang YX.

Nan Fang Yi Ke Da Xue Xue Bao. 2007 Aug;27(8):1199-202, 1205. Chinese.

8.

FLZ protects dopaminergic neuron through activating protein kinase B/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson's disease models.

Bao XQ, Kong XC, Qian C, Zhang D.

Neuroscience. 2012 Jan 27;202:396-404. doi: 10.1016/j.neuroscience.2011.11.036. Epub 2011 Nov 25.

PMID:
22138155
9.

Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins.

Kanagaraj N, Beiping H, Dheen ST, Tay SS.

Neuroscience. 2014 Jul 11;272:167-79. doi: 10.1016/j.neuroscience.2014.04.039. Epub 2014 Apr 30.

PMID:
24792712
10.

Docosahexaenoic acid provides protective mechanism in bilaterally MPTP-lesioned rat model of Parkinson's disease.

Hacioglu G, Seval-Celik Y, Tanriover G, Ozsoy O, Saka-Topcuoglu E, Balkan S, Agar A.

Folia Histochem Cytobiol. 2012 Jul 4;50(2):228-38.

11.

Overexpression of TFAM, NRF-1 and myr-AKT protects the MPP(+)-induced mitochondrial dysfunctions in neuronal cells.

Piao Y, Kim HG, Oh MS, Pak YK.

Biochim Biophys Acta. 2012 May;1820(5):577-85. doi: 10.1016/j.bbagen.2011.08.007. Epub 2011 Aug 11.

PMID:
21856379
13.

Neuroprotective effects of puerarin on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson's disease model in mice.

Zhu G, Wang X, Wu S, Li X, Li Q.

Phytother Res. 2014 Feb;28(2):179-86. doi: 10.1002/ptr.4975. Epub 2013 Mar 20.

PMID:
23512787
14.

Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson's disease.

Castro-Caldas M, Carvalho AN, Rodrigues E, Henderson CJ, Wolf CR, Rodrigues CM, Gama MJ.

Mol Neurobiol. 2012 Oct;46(2):475-86. doi: 10.1007/s12035-012-8295-4. Epub 2012 Jul 8.

PMID:
22773138
15.

Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson's disease in vitro and in vivo.

Guo B, Xu D, Duan H, Du J, Zhang Z, Lee SM, Wang Y.

Biol Pharm Bull. 2014;37(2):274-85. Epub 2013 Dec 3.

16.

Activation of transcription factor MEF2D by bis(3)-cognitin protects dopaminergic neurons and ameliorates Parkinsonian motor defects.

Yao L, Li W, She H, Dou J, Jia L, He Y, Yang Q, Zhu J, Cápiro NL, Walker DI, Pennell KD, Pang Y, Liu Y, Han Y, Mao Z.

J Biol Chem. 2012 Oct 5;287(41):34246-55. doi: 10.1074/jbc.M112.367540. Epub 2012 Aug 13.

17.

Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

L'Episcopo F, Tirolo C, Caniglia S, Testa N, Serra PA, Impagnatiello F, Morale MC, Marchetti B.

J Neuroinflammation. 2010 Nov 23;7:83. doi: 10.1186/1742-2094-7-83.

18.

The TrkB-positive dopaminergic neurons are less sensitive to MPTP insult in the substantia nigra of adult C57/BL mice.

Ding YX, Xia Y, Jiao XY, Duan L, Yu J, Wang X, Chen LW.

Neurochem Res. 2011 Oct;36(10):1759-66. doi: 10.1007/s11064-011-0491-5. Epub 2011 May 12.

PMID:
21562748
19.
20.

Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease.

González H, Contreras F, Prado C, Elgueta D, Franz D, Bernales S, Pacheco R.

J Immunol. 2013 May 15;190(10):5048-56. doi: 10.4049/jimmunol.1203121. Epub 2013 Apr 15.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk